Product
Genetically Engineered Lymphocyte Therapy
2 clinical trials
15 indications
Indication
Recurrent Anaplastic Large Cell LymphomaIndication
Recurrent B-Cell Non-Hodgkin LymphomaIndication
Hodgkin LymphomaIndication
Mycosis FungoidesIndication
Recurrent Peripheral T-Cell LymphomaIndication
NOSIndication
Anaplastic Large Cell LymphomaIndication
B-Cell Non-Hodgkin LymphomaIndication
Hodgkin lymphomaIndication
Peripheral T-Cell LymphomaIndication
Follicular LymphomaIndication
Grade 2 Follicular LymphomaIndication
Grade 3 Follicular LymphomaIndication
Mantle Cell LymphomaIndication
Non-Hodgkin LymphomaClinical trial
Bispecific NK Engager AFM13 Combined With NK Cells for Patients With Recurrent of Refractory CD30 Positive Hodgkin or Non-Hodgkin LymphomasStatus: Active (not recruiting), Estimated PCD: 2025-04-15
Clinical trial
Phase I/II Study of Cellular Immunotherapy Using Central Memory-Enriched CD8+ T Cells Lentivirally Transduced to Express A CD19-Specific Chimeric Immunoreceptor Following Peripheral Blood Stem Cell Transplantation for Patients With High-Risk Intermediate Grade B-Lineage Non-Hodgkin LymphomaStatus: Active (not recruiting), Estimated PCD: 2013-10-03